Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Thyroid cancer
Stage/Subtype:  stage IV follicular thyroid cancer
Trial Type:  Treatment
Results 1-9 of 9 for your search:
Start Over
A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: BBI608-201, NCI-2014-01566, NCT01325441
Pasireotide and Everolimus in Treating Patients with Thyroid Cancer Refractory to Radioiodine
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: WCI1777-09, NCI-2011-03377, IRB00041909, NCT01270321
Pioglitazone Hydrochloride in Treating Patients with Thyroid Cancer
Phase: Phase II
Type: Treatment
Age: 18 to 75
Trial IDs: UMCC 2011.097, NCI-2012-01918, 2011.097, HUM00049615, NCT01655719
Dabrafenib with or without Trametinib in Treating Patients with Recurrent Thyroid Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: OSU 12064, NCI-2012-01700, 2012C0074, NCCNGSK20008, NCT01723202
Cabozantinib-S-Malate in Treating Patients with Refractory Thyroid Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: OSU 12154, NCI-2013-00554, 2012C0101, RU241210I, 9312, NCT01811212
Sorafenib Tosylate with or without Everolimus in Treating Patients with Advanced, Radioactive Iodine Refractory Thyroid Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: A091302, NCI-2014-00623, NCT02143726
Trametinib in Increasing Tumoral Iodine Incorporation in Patients with Recurrent or Metastatic Thyroid Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 13-157, NCI-2014-01106, 9446, NCT02152995
Implanted Fiducial Markers in Assessing Treatment Accuracy and Esophageal Toxicity in Patients with Solid Tumors Undergoing Spinal Stereotactic Radiosurgery
Phase: No phase specified
Type: Supportive care, Treatment
Age: 18 and over
Trial IDs: 2012-0190, NCI-2012-01244, NCT01624220
Vemurafenib and Iodine I 131 in Treating Patients with BRAF Mutant, Radioiodine-Refractory Thyroid Cancer
Phase: No phase specified
Type: Treatment
Age: 18 and over
Trial IDs: 14-031, NCI-2014-01210, NCT02145143
Start Over